{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:59:34Z","timestamp":1780379974415,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T00:00:00Z","timestamp":1235347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To evaluate the efficacy and tolerability of adjunctive levetiracetam in very young children (aged 1\u2003month to &lt;4\u2003years) with partial\u2010onset seizures inadequately controlled with one or two antiepileptic drugs.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> This multicenter, double\u2010blind, randomized, placebo\u2010controlled study consisted of a 48\u2010h inpatient baseline video\u2010EEG (electroencephalography) and a 5\u2010day inpatient treatment period (1\u2010day up\u2010titration; 48\u2010h evaluation video\u2010EEG in the last 2\u2003days). Children who experienced at least two partial\u2010onset seizures during the 48\u2010h baseline video\u2010EEG were randomized to either levetiracetam [40\u2003mg\/kg\/day (age 1 to &lt;6\u2003months); 50\u2003mg\/kg\/day (age \u22656\u2003months to &lt;4\u2003years] or placebo.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> Of 175 patients screened, 116\u2003patients were randomized [60 levetiracetam; 56 placebo; intent\u2010to\u2010treat (ITT) population], and 111 completed the study. The responder rate in average daily partial\u2010onset seizures frequency (48\u2010h video\u2010EEG monitoring; primary efficacy variable) was 43.1% for levetiracetam [modified ITT (mITT) = 58] versus 19.6% for placebo (mITT\u2003=\u200351; p=0.013), with odds ratio for response 3.11 [95% confidence interval (CI), 1.22\u20138.26]. The median percent reduction from baseline in average daily partial\u2010onset seizure frequency was 43.6% for levetiracetam and 7.1% for placebo with a median difference between treatment groups of 39.2% (95% CI, 17.5\u201362.2; p<jats:italic>\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). In general, levetiracetam was well tolerated. Treatment\u2010emergent adverse events were reported by 55.0% levetiracetam\u2010 and 44.6% placebo\u2010treated patients (ITT population). The most frequently reported adverse events were somnolence (13.3% levetiracetam, 1.8% placebo) and irritability (11.7% levetiracetam, 0% placebo).<\/jats:p><jats:p><jats:bold><jats:styled-content>Discussion:<\/jats:styled-content>\u2002<\/jats:bold> Adjunctive levetiracetam is an efficacious and well\u2010tolerated treatment for partial\u2010onset seizures in infants and young children.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2008.01981.x","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T14:57:22Z","timestamp":1235401042000},"page":"1141-1149","source":"Crossref","is-referenced-by-count":94,"title":["Adjunctive levetiracetam in infants and young children with refractory partial\u2010onset seizures"],"prefix":"10.1111","volume":"50","author":[{"given":"Jesus Eric","family":"Pi\u00f1a\u2010Garza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Nordli Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietz","family":"Rating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Schiemann\u2010Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Levetiracetam N01009 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00323-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb05998.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252941.50833.4a"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb06022.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.64.4_Spec_No.452"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10070"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.03.006"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15268"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.12.005"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2005.31504.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.01.005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000217916.00225.3a"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01090.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.02.004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.02.004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb06222.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electrocephalographic classification of epileptic seizures","volume":"22","author":"ILEA","year":"1981","journal-title":"Epilepsia"},{"key":"e_1_2_6_22_1","unstructured":"International Conference on Harmonisation Guideline for Good Clinical Practice [CPMP\/ICH\/135\/95](2002)ICH Topic E6 (R1) Guideline for good Clinical Practice.European Medicines Agency London. Available at:http:\/\/www.emea.europa.eu\/pdfs\/human\/ich\/013595en.pdf. Accessed March 6 2008."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(03)00041-2"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000297512.18364.40"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01201.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00931.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.41300.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01003.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00250-4"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000186800.18456.72"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847050-00004"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(91)90067-U"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307380201700603"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01981.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01981.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:53:49Z","timestamp":1697129629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01981.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01981.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01981.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}